{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:32:29Z","timestamp":1791307949099,"version":"4.3.1"},"reference-count":47,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2011,8,9]],"date-time":"2011-08-09T00:00:00Z","timestamp":1312848000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0023022","type":"journal-article","created":{"date-parts":[[2011,8,9]],"date-time":"2011-08-09T20:52:13Z","timestamp":1312923133000},"page":"e23022","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":47,"title":["Chronic Myeloid Leukemia Patients in Prolonged Remission following Interferon-\u03b1 Monotherapy Have Distinct Cytokine and Oligoclonal Lymphocyte Profile"],"prefix":"10.1371","volume":"6","author":[{"given":"Anna","family":"Kreutzman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Rohon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar","family":"Faber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karel","family":"Indrak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vesa","family":"Juvonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veli","family":"Kairisto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaroslava","family":"Voglov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjatta","family":"Sinisalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Em\u00edlia","family":"Flochov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jukka","family":"Vakkila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petteri","family":"Arstila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimmo","family":"Porkka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satu","family":"Mustjoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2011,8,9]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia.","volume":"96","author":"MW Deininger","year":"2000","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia.","volume":"23","author":"A Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.","volume":"362","author":"H Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.","volume":"362","author":"G Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","article-title":"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.","volume":"109","author":"P Rousselot","year":"2007","journal-title":"Blood"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"420","DOI":"10.2174\/138945011794815301","article-title":"Interferon alpha for Treatment of Chronic Myeloid Leukemia.","volume":"12","author":"B Simonsson","year":"2011","journal-title":"Curr Drug Targets"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"532","DOI":"10.7326\/0003-4819-114-7-532","article-title":"Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients.","volume":"114","author":"M Talpaz","year":"1991","journal-title":"Ann Intern Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1182\/blood.V79.8.1920.1920","article-title":"Detection of minimal residual disease by polymerase chain reaction in Philadelphia chromosome-positive chronic myelogenous leukemia following interferon therapy.","volume":"79","author":"MS Lee","year":"1992","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","article-title":"Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.","volume":"363","author":"C Preudhomme","year":"2010","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.leukres.2010.04.010","article-title":"Pegylated IFN-alpha2a combined to imatinib mesylate 600 mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600 mg daily alone.","volume":"35","author":"FE Nicolini","year":"2011","journal-title":"Leuk Res"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.3324\/haematol.2009.021246","article-title":"The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase.","volume":"95","author":"F Palandri","year":"2010","journal-title":"Haematologica"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1200\/JCO.2009.25.5075","article-title":"Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia.","volume":"28","author":"A Burchert","journal-title":"J Clin Oncol"},{"key":"ref13","first-page":"6629","article-title":"Effect of recombinant alpha-interferon on the expression of the bcr-abl fusion gene in human chronic myelogenous human leukemia cell lines.","volume":"47","author":"DF Andrews 3rd","year":"1987","journal-title":"Cancer Res"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1182\/blood.V78.2.499.499","article-title":"Interferon-alpha overrides the deficient adhesion of chronic myeloid leukemia primitive progenitor cells to bone marrow stromal cells.","volume":"78","author":"C Dowding","year":"1991","journal-title":"Blood"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.1182\/blood.V87.9.3883.bloodjournal8793883","article-title":"Interferon-alpha restores normal beta 1 integrin-mediated inhibition of hematopoietic progenitor proliferation by the marrow microenvironment in chronic myelogenous leukemia.","volume":"87","author":"R Bhatia","year":"1996","journal-title":"Blood"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/sj.leu.2400723","article-title":"Expression of interferon regulatory factor (IRF) genes and response to interferon-alpha in chronic myeloid leukaemia.","volume":"11","author":"A Hochhaus","year":"1997","journal-title":"Leukemia"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1182\/blood.V94.7.2200.419a33_2200_2207","article-title":"BCR\/ABL mRNA and the P210(BCR\/ABL) protein are downmodulated by interferon-alpha in chronic myeloid leukemia patients.","volume":"94","author":"F Pane","year":"1999","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1182\/blood.V97.11.3491","article-title":"Expression of interferon consensus sequence binding protein induces potent immunity against BCR\/ABL-induced leukemia.","volume":"97","author":"M Deng","year":"2001","journal-title":"Blood"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/sj.leu.2400965","article-title":"Association of HLA phenotype and response to interferon-alpha in patients with chronic myelogenous leukemia.","volume":"12","author":"J Cortes","year":"1998","journal-title":"Leukemia"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/sj.leu.2400919","article-title":"Evidence for specific immune response against P210 BCR-ABL in long-term remission CML patients treated with interferon.","volume":"12","author":"T Oka","year":"1998","journal-title":"Leukemia"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1182\/blood-2002-02-0659","article-title":"Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia.","volume":"101","author":"A Burchert","year":"2003","journal-title":"Blood"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nature07815","article-title":"IFNalpha activates dormant haematopoietic stem cells in vivo.","volume":"458","author":"MA Essers","year":"2009","journal-title":"Nature"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1200\/JCO.20.1.214","article-title":"Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa.","volume":"20","author":"FX Mahon","year":"2002","journal-title":"J Clin Oncol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1182\/blood.V98.10.3074","article-title":"Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders.","volume":"98","author":"F Bonifazi","year":"2001","journal-title":"Blood"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/sj.leu.2401245","article-title":"Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia.","volume":"13","author":"MJ Pongers-Willemse","year":"1999","journal-title":"Leukemia"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1182\/blood-2009-12-256800","article-title":"Mono\/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy.","volume":"116","author":"A Kreutzman","year":"2010","journal-title":"Blood"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.4049\/jimmunol.152.6.2860","article-title":"Unique selection determinant in polyclonal V delta 2-J delta 1 junctional regions of human peripheral gamma delta T lymphocytes.","volume":"152","author":"TM Breit","year":"1994","journal-title":"J Immunol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1189\/jlb.71.4.669","article-title":"IFN-alpha2a induces IP-10\/CXCL10 and MIG\/CXCL9 production in monocyte-derived dendritic cells and enhances their capacity to attract and stimulate CD8+ effector T cells.","volume":"71","author":"E Padovan","year":"2002","journal-title":"J Leukoc Biol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/leu.2008.273","article-title":"Does chemotherapy modify the immune surveillance of hematological malignancies?","volume":"23","author":"AJ Barrett","year":"2009","journal-title":"Leukemia"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(05)70931-4","article-title":"Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial.","volume":"365","author":"M Bocchia","year":"2005","journal-title":"Lancet"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1038\/sj.leu.2404858","article-title":"Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study.","volume":"21","author":"JM Rojas","year":"2007","journal-title":"Leukemia"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1182\/blood-2003-01-0150","article-title":"Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation.","volume":"102","author":"K Rezvani","year":"2003","journal-title":"Blood"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1038\/sj.leu.2404892","article-title":"Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia.","volume":"21","author":"BN Savani","year":"2007","journal-title":"Leukemia"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1182\/blood-2008-05-158253","article-title":"Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib.","volume":"113","author":"AS Yong","year":"2009","journal-title":"Blood"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1600-0609.2010.01501.x","article-title":"Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy.","volume":"85","author":"P Rohon","year":"2010","journal-title":"Eur J Haematol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/leu.2009.46","article-title":"Clonal expansion of T\/NK-cells during tyrosine kinase inhibitor dasatinib therapy.","volume":"23","author":"S Mustjoki","year":"2009","journal-title":"Leukemia"},{"key":"ref37","first-page":"2675","article-title":"A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia.","volume":"59","author":"JJ Molldrem","year":"1999","journal-title":"Cancer Res"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/79526","article-title":"Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia.","volume":"6","author":"JJ Molldrem","year":"2000","journal-title":"Nat Med"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"e11770","DOI":"10.1371\/journal.pone.0011770","article-title":"PR1-specific T cells are associated with unmaintained cytogenetic remission of chronic myelogenous leukemia after interferon withdrawal.","volume":"5","author":"S Kanodia","year":"2010","journal-title":"PLoS One"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1146\/annurev.immunol.18.1.975","article-title":"[gamma][delta] cells: a right time and a right place for a conserved third way of protection.","volume":"18","author":"AC Hayday","year":"2000","journal-title":"Annu Rev Immunol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.molmed.2009.04.005","article-title":"Natural killer and gammadelta T cells in haematological malignancies: enhancing the immune effectors.","volume":"15","author":"J Rey","year":"2009","journal-title":"Trends Mol Med"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S1471-4906(01)02110-X","article-title":"Human gammadelta T cells: a nonredundant system in the immune-surveillance against cancer.","volume":"23","author":"M Ferrarini","year":"2002","journal-title":"Trends Immunol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"e16700","DOI":"10.1371\/journal.pone.0016700","article-title":"Anti-leukemia activity of in vitro-expanded human gamma delta T cells in a xenogeneic ph leukemia model.","volume":"6","author":"GM Siegers","year":"2011","journal-title":"PLoS One"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1182\/blood-2004-09-3458","article-title":"NK cells that are activated by CXCL10 can kill dormant tumor cells that resist CTL-mediated lysis and can express B7-H1 that stimulates T cells.","volume":"105","author":"A Saudemont","year":"2005","journal-title":"Blood"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1146\/annurev.immunol.24.021605.090720","article-title":"The eosinophil.","volume":"24","author":"ME Rothenberg","year":"2006","journal-title":"Annu Rev Immunol"},{"key":"ref46","first-page":"7451","article-title":"The CC chemokine MCP-1\/CCL2 in pancreatic cancer progression: regulation of expression and potential mechanisms of antimalignant activity.","volume":"63","author":"P Monti","year":"2003","journal-title":"Cancer Res"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"e164","DOI":"10.1016\/j.leukres.2009.03.024","article-title":"CD8+ memory T cells predominate over naive T cells in therapy-free CML patients with sustained major molecular response.","volume":"33","author":"K Usuki","year":"2009","journal-title":"Leuk Res"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0023022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T17:08:57Z","timestamp":1686244137000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0023022"}},"subtitle":[],"editor":[{"given":"Paul","family":"Proost","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2011,8,9]]},"references-count":47,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2011,8,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0023022","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,9]]}}}